Peripheral Blood Lymphocyte Subgroups in Patients Undergoing Hemodialysis with Medium Cutoff Membranes and High-Flux

Nuri Baris Hasbal1, Mustafa Sevinc2, Vuslat Yilmaz3

  • 1Division of Nephrology, Department of Internal Medicine, Koc University School of Medicine, Istanbul, Turkey.

Blood Purification
|September 1, 2024
PubMed

Insights

Medium cutoff (MCO) membranes, used in dialysis for end-stage kidney disease (ESKD), promote an anti-inflammatory immune response. MCO membranes favorably modulated lymphocyte subpopulations, suggesting improved patient outcomes.

Area of Science:

  • Nephrology
  • Immunology
  • Biomedical Engineering

Background:

  • Chronic kidney disease (CKD) is a growing global health concern with high mortality rates.
  • Inflammation is a key factor in CKD pathogenesis, but its mechanisms are not fully understood.
  • Medium cutoff (MCO) membranes offer potential benefits in hemodialysis by clearing toxins while minimizing albumin loss.

Purpose of the Study:

  • To investigate the effects of MCO versus high-flux (HF) membranes on peripheral blood lymphocyte subpopulations in hemodialysis patients.
  • To assess the immunomodulatory impact of different dialysis membrane types.

Main Methods:

  • Twenty-four end-stage kidney disease (ESKD) patients participated in the study.
  • Each patient underwent 36 hemodialysis sessions, alternating between MCO and HF membranes.
  • Lymphocyte subsets were analyzed using immunophenotyping via flow cytometry.

Main Results:

  • MCO membranes led to a significant increase in Natural Killer (NK) cells.
  • T helper 2 (Th2) and T follicular helper (Tfh) cells increased with MCO, while Th1 cells decreased post-HF.
  • Regulatory T (Treg) cells remained stable with MCO but decreased with HF dialysis.

Conclusions:

  • MCO dialysis demonstrated an anti-inflammatory effect, indicated by increased Th2/Tfh cells and stable Treg cells.
  • MCO membranes positively influenced NK cell populations.
  • These findings suggest MCO membranes have the potential to modulate immune responses and improve outcomes in ESKD patients.
Abstract